Phosphorylation of WRN by CDK1 is not required for the initial processing of the DSB, but is crucial to sustain the subsequent long-range end resection, corroborating previous evidence for a role ...

Nimbus' pipeline includes a WRN inhibitor in Phase 1/2 clinical development (NCT06898450) and a diverse portfolio of preclinical programs across oncology, immunology, and metabolism, including a ...

SAN DIEGO & BERLIN, Germany, June 04, 2025--Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG ...

image: ISM2196 is a novel, potent WRN inhibitor, designed with the assistance of Alchemistry, one of the latest modules of Chemistry 42. view more . Credit: Insilico Medicine ...